CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—OpGen has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help health care providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.
Under the terms of the agreement, OpGen will commercialize the Acuitas Rapid Test for Pathogen ID and resistance genes on Thermo Fisher’s mid-throughput real-time PCR system. The effort will be supported by local labs that will be able to interpret results using customized analysis software and OpGen’s cloud-based Acuitas Lighthouse Knowledgebase to match genomic analysis data with antibiotic susceptibility information to identify microbial infections in individual patients.
OpGen, 301-869-9683